Sangui BioTech:

- World leader in wound care acquires SastoMed GmbH

Witten, July, 03 2018: As reported by SastoMed GmbH and Mölnlycke Heath Care in a joint press release, Mölnlycke Health Care has fully taken over SastoMed GmbH, to which Sangui BioTech GmbH has licensed the Granulox wound spray, with effect from July, 02 .2018.

"The fact that the Mölnlycke Group, one of the world's largest and most renowned wound care companies, will invest in further marketing the wound spray developed by Sangui, makes us proud and confirms our long - term commitment. We see the sale as the next logical step, with the help of Mölnlycke's worldwide sales organization, to further and faster increase the availability of Granulox. We thank the team of SastoMed GmbH in this context, whose work Granulox owes its market acceptance. In the course of the acquisition of the SastoMed GmbH by Mölnlycke the Sangui Bio Tech GmbH took advantage of the opportunity, by establishment of a know-how and patent collecting company and introduction of the still continuing existing license agreement with the SastoMed GmbH into this, to separate the wound spray business - also in anticipation of future activities - from the remaining business of Sangui BioTech GmbH", Hubertus Schmelz, Managing Director of Sangui BioTech GmbH comments on the transaction.

References:
Press release Mölnlycke
http://news.cision.com/molnlycke/r/molnlycke-acquires-german-wound-care-company-sastomed-gmbh,c2566079

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.